AbbVie’s blockbuster eye drug Restasis under threat as FDA approves Viatris’ copycat esagonowsky Wed, 02/02/2022 – 15:56 More: AbbVie's blockbuster eye drug Restasis under threat as FDA approves Viatris' copycat Source: fierce
read moreHumira rings up $20.7B in 2021, but AbbVie still mum on post-biosimilar expectations kdunleavy Wed, 02/02/2022 – 11:52 More: Humira rings up .7B in 2021, but AbbVie still mum on post-biosimilar expectations Source: fierce
read moreDHL earmarks $400M to expand its pharma, medical device supply chain network this year jkeenan Wed, 02/02/2022 – 10:44 More: DHL earmarks 0M to expand its pharma, medical device supply chain network this year Source: fierce
read moreNovartis says Leqvio launch will feature a ‘modest initial ramp,’ but blockbuster potential awaits esagonowsky Wed, 02/02/2022 – 10:22 More: Novartis says Leqvio launch will feature a 'modest initial ramp,' but blockbuster potential awaits Source: fierce
read moreNovo touts diabetes, obesity growth, but Wegovy supply woes remain top of mind fkansteiner Wed, 02/02/2022 – 09:17 More: Novo touts diabetes, obesity growth, but Wegovy supply woes remain top of mind Source: fierce
read moreBoost for patients with life-threatening conditions who require access to medicines not yet authorised for marketing More: Early risers: life-changing medical scheme given legal revitalisation Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals